Wegovy Just Became a Liver Drug.

The Data That Opened the Door

The ESSENCE trial enrolled 1,197 patients in total with biopsy-confirmed MASH and F2–F3 fibrosis; the first cohort of roughly 800 patients was analyzed in the Part 1 interim analysis at 72 weeks. The results were hard to argue with.

63% of patients on semaglutide saw their liver inflammation resolve without their scarring getting worse. Only 34% on placebo could say the same. That's a 29-percentage-point gap, which in liver disease trials qualifies as enormous.

On the scarring side, 37% of semaglutide patients improved by at least one fibrosis stage, compared to 22% on placebo. And here's the part that excites researchers: secondary analyses suggest these liver benefits aren't fully explained by weight loss alone. Patients on semaglutide showed greater liver improvement than placebo patients who lost similar amounts of weight, hinting at direct effects on the liver itself.

The FDA granted accelerated approval based on these histologic (tissue-level) results. Full confirmation will come from part 2 of ESSENCE, expected around 2029, which will track hard outcomes like cirrhosis progression, transplants, and deaths.

Novo's India Chess Match

Novo Nordisk isn't just filing paperwork in India; it's waging a full-scale market offensive. The company launched Wegovy for obesity in June 2025 and followed with Ozempic for diabetes in December. Now the MASH label expansion gives it a three-indication franchise built on a single molecule.

The timing is deliberate. Semaglutide's Indian patent expired in March 2026, and more than 40 generic manufacturers are racing to market with cheaper versions. Novo's response has been aggressive price cuts—36% on Ozempic starter doses and 48% on Wegovy starter doses—combined with local partnerships: Wegovy is co-marketed as Poviztra through Emc Pharma, while Ozempic sells as Extensior via Abbott India.

The strategy is working so far. After the April 2026 price cuts, combined sales of branded semaglutide products surged to 32,000 units, a 40% jump month over month. Novo's long-term target? $1 billion in annual Indian Wegovy sales within five to seven years.

Adding the MASH indication is rocket fuel for that ambition. With nearly 40% of Indian adults carrying fatty liver and tens of millions at risk of progressing to scarring, the addressable patient pool is massive.

The Bigger Picture: Indication Stacking as Strategy

Zoom out and you can see what Novo (and the entire GLP-1 industry) is really building. Semaglutide now carries labels for obesity, type 2 diabetes, cardiovascular risk reduction, and MASH. Each new indication isn't just incremental revenue; it's a reason for doctors to prescribe and patients to stay on the drug.

BMO Capital Markets estimated the MASH indication alone could add $1.9 billion in peak worldwide revenue to Wegovy. And the competitive moat is real, at least temporarily. Eli Lilly's tirzepatide showed impressive phase 2 data in MASH (up to 74% resolution of liver inflammation), but it doesn't have an FDA label yet. Novo's first-mover advantage in MASH could last a couple of years.

Then there's Madrigal Pharmaceuticals and its liver-targeted drug Rezdiffra (resmetirom), which was actually the first MASH drug approved anywhere, back in March 2024. Analysts don't see this as a winner-take-all battle. GlobalData projects Rezdiffra hitting $1.1 billion in sales by 2026 and climbing to $4.8 billion by 2031, even with Wegovy in the mix.

The emerging consensus? GLP-1s like Wegovy will serve as foundational therapy for the many MASH patients who are also obese or diabetic. Liver-directed drugs like Rezdiffra will target patients with more advanced fibrosis, lean MASH (yes, thin people get fatty liver too), or those who can't tolerate GLP-1 side effects. Eventually, many patients may get both.

What to Watch

India's approval is a signal, not just a headline. It tells us that major regulators outside the U.S. are comfortable extending GLP-1 labels into liver disease based on the ESSENCE data. The European Medicines Agency already issued a positive opinion for semaglutide in MASH (under the brand name Kayshild), with formal EU approval expected soon. Japan is reviewing a filing submitted in May 2025.

For the hundreds of millions of people worldwide living with fatty liver disease, the treatment landscape just shifted from "change your lifestyle and hope for the best" to something that looks a lot more like real medicine. Whether that medicine costs ₹5,660 a month or ₹16,400 depends on your dose, your country, and how fast the generics show up.

But for the first time, a GLP-1 drug has a liver disease label in one of the countries that needs it most. The obesity drug's side hustle might end up being its main act.

The Biotech Rescue Deal That Needed a Flowchart

Jasper Therapeutics was six months from running out of cash. Instead of folding, it engineered a three-party deal involving a reverse merger, $132 million in rescue financing, and a licensing play that could challenge a drug the FDA wants to pull from the market.